2. Bayesian adaptive designs for
early-phase clinical trials. We have developed a series of adaptive
designs for early phase clinical trials, such as phase I dose-finding
trials in oncology. Our recent activities involve the development of
seamless early phase trials, subgroup discovery for biomarker trials, etc.